BusinessAkari Therapeutics to Attend Upcoming Investor Conferences In NovemberBy Nasdaq OMXNov 11, 2016, 12:00 PM UTC
BusinessOcera Therapeutics Reports Third Quarter 2016 Financial Results and Company UpdateBy Nasdaq OMXNov 2, 2016, 1:05 PM UTC
BusinessOcera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016By Nasdaq OMXOct 24, 2016, 1:05 PM UTC
BusinessFate Therapeutics Receives FDA Orphan Drug Designation for ProTmune™ in Allogeneic Hematopoietic Cell TransplantationBy Nasdaq OMXSep 26, 2016, 12:00 PM UTC
BusinessOcera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver FailureBy Nasdaq OMXSep 21, 2016, 8:05 PM UTC
BusinessOcera to Present at the Ladenburg Thalmann 2nd Annual Healthcare ConferenceBy Nasdaq OMXSep 20, 2016, 1:10 PM UTC
BusinessOcera Initiates Phase 1 Clinical Study of Orally Available OCR-002 in Patients with Cirrhosis for the Prevention of Hepatic EncephalopathyBy Nasdaq OMXSep 19, 2016, 1:05 PM UTC
BusinessAkari Therapeutics to Present at Upcoming Investor Conferences on September 27 and 28 in New York CityBy Nasdaq OMXSep 16, 2016, 4:18 PM UTC
